Related Experiment Videos
Periocular corticosteroids in diabetic papillopathy
A M Mansour1, M A El-Dairi, M A Shehab
1Department of Ophthalmology, American University of Beirut, Beirut, Lebanon. r.ahmad@cyberia.net.lb
Eye (London, England)
|April 20, 2004
Summary
Periocular corticosteroids significantly shorten the duration of diabetic papillopathy (DP) in patients with diabetes. This treatment offers faster visual recovery and improved visual field outcomes, though intraocular pressure requires monitoring.
Area of Science:
- Ophthalmology
- Endocrinology
- Diabetic Retinopathy Research
Background:
- Diabetic papillopathy (DP) is a condition affecting the optic nerve in diabetic patients.
- Current treatment options for DP have limited efficacy and prolonged recovery times.
Observation:
- A prospective study evaluated five adult-onset diabetic patients with symptomatic DP.
- Patients received superonasal subtenon injections of corticosteroids.
- Visual fields and fluorescein angiography were performed pre- and post-treatment.
Findings:
- Periocular corticosteroid injections reduced DP duration from a median of 5 months to 3 weeks.
- Median recovery time for best-spectacle-corrected visual acuity was 2 weeks.
- Treated eyes showed less constricted visual fields and faster visual recovery in sequential cases.
Implications:
- Periocular corticosteroids demonstrate therapeutic potential for diabetic papillopathy.
- Angiostatic and antioedema effects may contribute to treatment success.
- Monitoring intraocular pressure is crucial during corticosteroid treatment for DP.